$75 Million

Audentes Therapeutics

Follow-on Offering

Bookrunner, April 2017

Audentes Therapeutics is a biotechnology company focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by a single gene defect. The Company has developed a proprietary gene therapy platform that aims to deliver a functional copy of a defected gene and the resulting production of the desired protein in target tissues. The Company has developed four product candidates, AT132, AT342, AT982 and AT307. The Company’s lead product candidate, AT132, is in development for the treatment of X-Linked Myotubular Myopathy, or XLMTM.